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Abstract
Background: Globally, heart failure (HF) has been recognized as one of the major cardiovascular disorder with high
morbidity, mortality and considerable social impact. In Sub Saharan African countries, HF has turned out as a leading
form of cardiovascular diseases, and has considerable socioeconomic impact. However, there are differences in clinical
characteristics and survival status among patients with preserved (HFpEF) and reduced (HFrEF) ejection fraction. The
aim of this study is to outline the clinical characteristics and medication profile, assess the survival status and
prognostic factors of Ethiopian HF patients with HFrEF and HFpEF.
Methods: A retrospective cohort study was carried out and we employed medical records of patient’s, admitted as a
result of HF to the University of Gondar Referral Hospital in the period between December 02, 2010 and December 01,
2015 due to HF. Kaplan Meier curve was used to analyze the survival status and log rank test was used to compare the
curves. Cox regression was used to analyze independent predictors of mortality in all HF patients.
Results: Of the 850 patients who were admitted due to HF, 311 patients met the inclusion criteria. Majority of the
patients had HFpEF (52.73%) and tend to be women (76.22%). They predominantly had etiologies of valvular and
hypertensive heart diseases, and took calcium channel blockers and anticoagulants. Conversely, patients with HFrEF
had etiologies of ischemic heart disease and dilated cardiomyopathy and were prescribed angiotensine converting
inhibitors (ACEI) and beta blockers. Kaplan Meier curves and Log rank test (p = 0.807) showed that there was no
statistically significant difference in the mortality difference among patients with HFpEF and HFrEF. On the other hand,
Cox regression analysis showed advanced age, lower sodium level, higher creatinine level and absence of medications
like ACEI, spironolactone and statins independently predicted mortality in all HF patients.
Conclusions: Different clinical characteristics were found in both groups of HF patients. There was no difference in
survival outcome between patients with HFrEF and HFpEF.
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Background
Heart failure (HF) is one of the major cardiovascular
disorder with high morbidity and mortality and rising
costs, which account for 1–2% of the annual health
budget of most developed nations [1, 2]. HF primarily
involves (affects) people with advanced age, and inci-
dence and prevalence increases progressively in those
age > 60 years [3]. The most frequent prevalence esti-
mate for the adult population at large is 2% and more
than 10% particularly in those aged 75 years and
older [2, 4–6]. In Sub Saharan African countries
(SSA), HF has turned out as a leading form of cardio-
vascular disease, and has considerable socioeconomic
impact owing to its high prevalence, mortality and
impact on young generations [7]. Unlike developed
nations, the most prevailing causes of HF in Africans
remains largely non ischemic [7]. Two third of HF
cases in SSA are mainly secondary to Hypertension
(HTN), cardiomyopathy and rheumatic heart disease
[7, 8]. In contrast, in industrialized nations, coronary* Correspondence: Befekadutamrat@gmail.com
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artery disease, either alone or in combination with
HTN, is the prominent cause of HF [9, 10].
Left ventricular dysfunction (LVD) is categorized into
systolic and diastolic dysfunction. A LVEF above 50%
and below 40 are considered reserved and reduced ejec-
tion fractions, respectively, leaving an intermediary range
of 40 to 50% [11]. Irregularity in the filling properties or
capacity of the left ventricle in patients with LVEF > 50
is used to classify diastolic dysfunction [11, 12]. HF is
usually considered typical when presenting in patients
with dilated hearts and systolic dysfunction (ejection
fraction (EF) < 40%). As a result, the most therapeutic
evidence, including effective pharmacological and device
therapies that have led to impressive improvements in
survival is in this group of patients with HFrEF. By con-
trast, most clinical trials excluded patients with HF with
preserved ejection fraction (HFpEF > 50%) [11, 12].
In the past three decades, prevalence of HF is on the
rise.[3, 13, 14]. Demographically, prevalence of HF has cer-
tain difference between patients with systolic dysfunction
(SDf) and diastolic dysfunction (DDf). Most patients with
DDf are usually older age and female, and have left ven-
tricular hypertrophy and arterial hypertension [15–18].
Moreover, there are disparities on the prognosis of patients
with SDf and DDf as some researches demonstrated that
morbidity and mortality is worse in the earlier group while
other studies emphasize that there is no convincing dis-
crepancy in prognosis between these groups [13, 19–22].
To the best of our knowledge, unlike western countries, we
did not found sufficient studies on the clinical characteris-
tics of patients with HF with reduced ejection fraction
(HFrEF) and HFpEF in SSA countries. Hence, we aimed to
evaluate HF patient’s clinical characteristics and outcome,
and medication profile based on patients recorded EF




We retrospectively assessed medical transcript of pa-
tients who had been admitted with a diagnosis of HF in
Internal Medicine ward of GURH in the period between
December 02, 2010 and December 01, 2015. Patients
who had been diagnosed HF, are 18 years of age or older,
and with presence of two or more of the adapted
Framingham criteria or presence of one major criteria
and two minor criteria has been included in the study.
Major criteria include: presence of sign and symptoms
of raised jugular venous pressure, paroxysmal nocturnal
dyspnea, clinical cardiomegaly confirmed by chest X- ray,
basal crepitation, third heart sound, pulmonary edema
confirmed by chest X- Ray, hepatojugular reflux and acute
pulmonary edema. Minor criteria include: heart rate >120
beats per minute, orthopnea, exertional dyspnea, nocturnal
cough, hepatomegaly, pleural effusion, and peripheral
edema. Exclusion criteria were patients who had concomi-
tant infection in addition to HF, patients who did not have
echocardiography record, patients who were New York
Heart Association (NYHA) Class I and class II during ad-
mission and patients who did not have laboratory analysis
records on complete blood count, electrolytes and creatin-
ine level. The internal medicine ward received around 850
patients during the study period and 539 were excluded
from the study based on the exclusion criteria.
Patients were grouped based on their LVEF record
into two: patients with HFpEF (LVEF ≥ 50%) and patients
with HFrEF (LVEF < 50%). Ejection fraction of the partic-
ipants were measured using echocardiogram during
their first admission to the internal medicine ward by a
radiologist. Survival status of the patients were recorded
based on their vital status record on last hospital dis-
charge from internal medicine ward or the last time pa-
tient’s came for routine checkup or to refilled their
medication. Patient’s data was collected by two clinical
pharmacists (co – authors) during the study period.
Hypertension was determined as blood pressure 140/
90 mmHg or more, anemia as hemoglobin level < 13 g/
dl for men and <12 g/dl for women.
The etiology of HF was determined based on the fol-
lowing algorism: Ischemic, when the patient was diag-
nosed with Ischemic heart disease (IHD); Valvular, when
there was moderate valulopathy with no IHD; hyperten-
sive, when there was previous history of hypertension
but no evidence of additional cardiovascular disease; di-
lated cardiomyopathy (DCMP), when there was no other
known cardiac cause and had LVEF < 50%; and Cor pul-
monale, when right sided heart failure without left ven-
tricular dysfunction is present.
Statistics
Statistical analysis was conducted for both quantitative and
qualitative variables. Group variables were indicated in per-
centage and Chi square test was used. A probability of type
I error <5% was considered significant. Continuous vari-
ables were revealed in mean ± SD and independent t – test
was used with a probability of type I error < 5% considered
significant. Kaplan – Meier survival curves were designed
and analyzed with the Mantel log rank test to measure the
significance. Univariate Cox regression analysis was used to
determine the co-factors with momentous outcome on all-
cause mortality. Multivariate Cox regression analysis was
implemented to determine the independent foreboding fac-
tors for all-cause death. All data were analyzed with SPSS
version 20.0 (SPSS Inc. Chicago, IL) software for windows.
Results
Of 850 patients who were admitted to GURH due to HF,
in the period between December 02, 2010 and December
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01, 2015, 311 patients met the inclusion criteria. From
the study group, 164 patients had HFpEF (EF ≥ 50%)
and the remaining participants (147) had HFrEF (EF <
50%). Table 1 shows baseline clinical characteristics of
the two groups. The mean age of the participants were
53.58 (±16.902) years with no significant divergence
among the groups (54.20 (±16.587) Vs.52.88 (±17.246),
P = 0.496), and women accounted for the majority of
patients with LVEF ≥ 50 (76.22% vs. 62.59%, P = 0.009).
Analysis of cardiovascular risk factors such as hyperten-
sion and diabetes, other co morbidities like anemia,
atrial fibrillation, and NYHA functional class revealed
no compelling variance among the groups. However,
heart failure etiology clearly distinguished between the
HFrEF and HFpEF groups. In the earlier groups Ische-
mic heart disease (IHD) (21.09% vs. 10.98%, P = 0.015)
and DCMP (21.77% vs. 4.27%, P = <0.001) were more
prevalent; whereas, VHD (34.01% vs. 45.96%, P = 0.020)
and HHD (11.56% vs. 20.12%, P = 0.040) were more
prevalent in the later groups. There were also signifi-
cant differences between patients with HFpEF and
HFrEF in their heart rate (95.60 (±21.177) Vs.89.93
(±16.287), P = 0.009).
Medical treatment
Table 2 compares treatments at discharge in patients in
the two groups. There were no significant difference in
the prescription of diuretics, spironolactone, antiplatelet
agents, digoxin and statins. Patients classified as having
depressed LVEF were usually prescribed angiotensin
converting enzyme inhibitor (ACEI) and beta blockers.
On the other hand, anti-coagulants and calcium channel
blockers were more frequently prescribed in patients
with HFpEF.
Results of laboratory analyses and echocardiograms
Higher hemoglobin levels were measured in patients
with reduced ejection fraction than preserved ejection
fraction (13.31 ± 3.76 vs. 12.47 ± 3.08, P = 0.031). Greater
ventricular dimension were recorded in patients with
HFrEF (57.38 ± 9.07 vs. 46.10 ± 8.64, P = < 0.001). The
mean EF in patients with preserved and reduced EF
were 62.57 ± 8.62 and 40.36 ± 6.81respectively (Table 3).
Survival analysis
The mean duration of follow up was 24.56 ± 17.79 months.
Mortality were 14.02% in patients with HFpEF (23 pa-
tients) and 14.29% in patients with HFrEF (21 patients).
Kaplan Meier survival curves (Fig. 1) shows there were no
significant difference in survival status of patients with
HFrEF and HFpEF (Log Rank test, P = 0.807). On the other
hand, univariate Cox regression analysis showed that age,
sodium level, creatinine level, IHD, Spironolactone, and
digoxin were significantly associated with morality in
patients with HF (Table 4). Multivariate Cox regression
analysis, including the significant predictors of mortality
Table 1 Clinical characteristics of Heart Failure patients based on Preserved of reduced ejection fraction
Variable Total patients (n = 311) LVEF ≥ 50% (n = 164) LVEF < 50% (n = 147) P value
Women, n (%) 217 (69.77) 125 (76.22) 92 (62.59) 0.009
Age, Years (mean ± SD) 53.58 (±16.902) 54.20 (±16.587) 52.88 (±17.246) 0.496
Anemia, n (%) 118 (37.94) 65 (39.63) 53 (36.05) 0.516
AF, n (%) 79 (25.41) 47 (28.66) 32 (21.77) 0.163
DM, n (%) 4 (1.29) 2 (1.22) 2 (1.36) 0.912
Hypertension, n (%) 97 (0.312) 56 (34.15) 41 (27.89) 0.235
Heart Rate ( mean ± SD) 92.88 (±19.166) 95.60 (±21.177) 89.93 (±16.287) 0.009
Systolic BP 122.75 (±24.231) 125.06 (±26.911) 120.18 (±20.651) 0.072
NYHA Functional Class 0.274
Class III, n (%) 82 (26.37) 39 (23.78) 43 (29.25)
Class IV, n (%) 229 (73.63) 125 (76.22) 104 (70.75)
Etiology
IHD, n (%) 49 (15.76) 18 (10.98) 31 (21.09) 0.015
HHD, n (%) 50 (16.08) 33 (20.12) 17 (11.56) 0.040
VHD, n (%) 127 (40.84) 77 (46.95) 50 (34.01) 0.020
DCMP, n (%) 39 (12.54) 7 (4.27) 32 (21.77) <0.001
Cor pulmonale, n (%) 14 (4.50) 9 (5.48) 5 (3.40) 0.376
Others, n (%) 32 (10.29) 20 (12.20) 12 (8.16) 0.243
AF atrial fibrillation, BP blood pressure, DCMP dilated cardiomyopathy DM diabetes mellitus, HHD hypertensive heart disease, IHD ischemic heart disease, NYHA
New York Heart Association, SD standard deviation
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identified on univariate Cox regression, showed that
advanced age, low sodium level, high creatinine level, and
absences of medications (spironolactone, ACEI and satin)
significantly predicted morality (Table 4).
Discussion
The present research analyzed data from a retrospective
observational cohort of HF patients to assess clinical
characteristics, medication profile and determinants of
mortality among HF patients with HFrEF and HFpEF
who were admitted at GURH.
The prevalence of HFpEF is on the raise with period
in developed nations [13, 23], varies depending on the
age of the patient, race and the cutoff values for LVEF.
In spite of that, there is a pervasive agreement that
HFpEF is prominent in more than a third of all patients
admitted with HF [19, 24–27]. In our study, the preva-
lence of HFpEF was 52.73% which was in alignment with
other studies [28–30]. A recent study conducted by L.
Martínez-Bra˜na et al. found that prevalence of HFpEF
in Spain was 72.2% [20]. A study carried out in Japan by
H. Kaneko et al. reported that prevalence of HFpEF was
72% [31]. In the Identification of Patients With Heart
Failure and PREserved Systolic Function: an epidemio-
logical regionalstudy (I PREFER) prevalence of HFpEF was
about 65% [32]. The disparity between these findings and
our study might be credited to sample size variation of the
study population, age of the patients, race and cutoff
values for LVEF during the study.
Patients with HFpEF are at advanced age, women and
more often have hypertension compared to patients with
HFrEF [20, 25, 27, 31]. In a systematic review reported
by E. E.S. van Riet et al., HFpEF was more prevalent with
age > 60 years and female gender [1]. In a meta-analysis
study, compared with patients with HFrEF, those with
HFpEF were older and more often women, and have a
history of hypertension [10]. The differences in patients’
backgrounds in our study were almost indistinguishable
to those of previous articles as patients with HFpEF in
this study were older and more often female.
Regarding the etiology of HF, hypertensive heart dis-
ease (HHD) and VHD are more common in patients
with HFpEF. Whereas, in patients with HFrEF, the most
prevalent causes were IHD and DCMP [19, 20, 24, 26].
A meta-analysis conducted by R.N. Doughty et.al re-
ported that, compared with the HFrEF patients, those
with HFpEF more often had a history of Hypertension
and less likely had IHD [10]. In I PREFER, Irbesartan
clinical trial and the Effects of Candesartan for the
Management of Patients With Chronic Heart Failure
(CHARM) program, it were reported that HHD was the
most important etiologic factor for the diagnosis of
HFpEF and CAD is the leading cause for patients with
HFrEF [32–34]. Similar finding were documented in
our study, where IHD and DCMP were the leading
etiologies for the prevalence of HFrEF; in contrast,
VHD and HHD were responsible for the diagnosis of
HFpEF. One of the interesting finding in our study was,
the impact of IHD as an etiology of HF in patients with
reduced ejection fraction. According to prior litera-
tures, most of the etiologies in African population were
non ischemic [7]. This disparity might indicate that the
progressive change in the epidemiological pattern of
the disease through time and the modification of indi-
viduals’ life style.
In terms of drug treatment, ACEI, Beta – Blockers and
Digitalis are mostly prescribed to patients with HFrEF
[19, 26, 31, 35–37]. However, CCB are usually indicated
for patients with HFpEF [38]. This is further supported
Table 2 Medication profile of heart failure patients based on
ejection fraction
Medication LVEF≥ 50 (n,164) LVEF < 50% (n,147) P value
ACEI n, % 34 (15.85) 80 (40.82) <0.001
Beta Blocker n, % 45 (21.95) 73 (36.73) <0.001
Diuretics n, % 146 (74.39) 136 (70.75) 0.290
Spironolactone n, % 114 (57.93) 95 (48.99) 0.359
Digoxin n, % 46 (23.17) 33 (17.69) 0.257
Statin n, % 24 (11.59) 30 (13.61) 0.180
Anticoagulants n, % 33 (17.07) 12 (14.70) 0.003
Antiplatelet agents n, % 33 (15.24) 39 (17.69) 0.181
CCB n, % 21 (9.76) 7 (4.76) 0.013
ACEI angiotensin converting enzyme inhibitor, CCB calcium channel blocker
Table 3 Laboratory and echocardiography results of heart failure patients based on ejection fraction
Variable LVEF≥ 50 (n,164) LVEF < 50% (n, 147) P value
Hgb (Mean ± SD) 12.47 ± 3.08 13.31 ± 3.76 0.031
Cr. (Mean ± SD) 1.1086 ± 0.774 1.0690 ± 0.536 0.598
Sodium (Mean ± SD) 134.86 ± 5.44 135.31 ± 7.92 0.563
LVEDD in mm (Mean ± SD) 46.10 ± 8.64 57.38 ± 9.07 <0.001
LVEF% (mean ± SD) 62.57 ± 8.62 40.36 ± 6.81 <0.001
Hgb hemoglobin, Cr creatinine, LVEDD left ventricular end diastolic diameter, LVEF left ventricular ejection fraction, SD standard deviation
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Log rank test, P = 0.807
Fig. 1 Kaplan Meier survival curves at 60 months for patients with preserved and reduced ejection fraction
Table 4 Predictors of mortality to all causes of heart failure
Univariate analysis Multivariate analysis
Variables Hazard ratio (95%CI) Hazard ratio (95%CI) P value
Gender Male 0.984 (0.521–1.857) 1.132 (0.463–2.766) 0.785
Age, Years Age, years 1.046 (1.025–1.068) 1.045 (1.016–1.076) 0.002
NYHA Class Class IV 1.549 (0.719–3.337) 1.267 (0.527–3.046) 0.597
Anemia Yes 1.483 (0.818–2.689) 0.708 (0.333–1.504) 0.369
Sodium, mEq/L 0.933 (0.896–0.972) 0.913 (0.851–0.980) 0.011
Creatinine, mg/dl 2.602 (2.052–3.300) 1.966 (1.369–2.824) <0.001
AF Yes 0.486 (0.225–1.051) 0.617 (0.171–2.224) 0.461
VHD Yes 0.636 (0.342–1.185) 1.420 (0.413–4.886) 0.578
IHD Yes 2.355 (1.182–4.691) 2.211 (0.397–12.331) 0.365
DCMP Yes 0.898 (0.352–2.290) 1.068 (0.240–4.743) 0.931
HHD Yes 1.036 (0.481–2.229) 1.272 (0.338–4.794) 0.722
LVEF 0.997 (0.975–1.020) 0.992 (0.958–1.027) 0.634
Diuritics Yes 0.877 (0.269–2.858) 0.690 (0.180–2.650) 0.589
Spironolactone Yes 0.388 (0.214–0.703) 0.343 (0.158–0.743) 0.007
ACEI Yes 0.952 (0.510–1.778) 0.258 (0.098–0.680) 0.006
Beta Blocker Yes 1.205 (0.659–2.204) 1.713 (0.766–3.832) 0.190
Digoxin Yes 0.313 (0.132–0.746) 0.407 (0.095–1.736) 0.224
Antiplatelates Yes 0.883 (0.435–1.793) 1.383 (0.352–5.436) 0.643
Anticoagulants Yes 1.700 (0.817–3.541) 2.429 (0.845–6.978) 0.099
Statin Yes 1.520 (0.768–3.010) 0.189 (0.037–0.972) 0.046
CCB Yes 1.555 (0.720–3.359) 0.815 (0.287–2.317) 0.701
ACEI angiotensin converting enzyme inhibitor, AF atrial fibrillation, CCB calcium channel blocker, DCMP dilated cardiomyopathy, HHD hypertensive heart disease,
IHD ischemic heart disease, LVEF left ventricular ejection fraction, NYHA New York Heart Association, VHD valvular heart disease
Factors included in multivariate Cox model include: Gender, Age, NYHA Class, presence of comorbidities such as anemia and AF, Common etiologies of HF such as
VHD, IHD,HHD, and DCMP, Use of medications such as Diuretics, Spironolactone, ACEI, Beta Blocker, Digoxin, Antiplatelates, Anticoagulants, Statin and CCB, and
laboratory values such as sodium and creatinine
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by 2016 ESC European heart failure guideline, as indi-
cated amlodipine in HF patients with preserved ejection
fraction and ventricular rhythm problem [39]. Unlike
HF with HFrEF, patients with HFpEF did not benefit
from the novel medications indicated to manage the
disease and improve morbidity and mortality. Hence,
there are few clinical trials on this group of patients
and trials already conducted on ACEI/Angiotensin
Receptor Blockers showed that there is no promising
influence on reducing the mortality rate in patients
with HFpEF [33, 40]. The CHARM Program study
showed no significant effect on mortality, but showed
significant benefit in preventing HF hospitalization
[34]. One of the proposed predictions by Y. Juillière et
al. was systemic hypertension is more frequently
associated with preserved ejection fraction, resulting a
higher rate of prescription of CCB. In contrast most of
the etiologies in patients with HFrEF are usually IHD
[38]. Similar findings were presented in our study,
where most of patients with HFpEF took CCB and anti-
coagulants since hypertension and AF were more
prevalent in this group of patients. However, ACEI and
Beta blockers were more recommended in patients with
HFrEF.
There is no clear cut variation in the long term clinical
outcomes of patients with HFpEF and HFrEF. Studies
conducted by Owan TE et al., F.P. Brouwers et al. and
H. Kaneko et al. reported that patient with HFpEF had
better prognosis than those with HFrEF [13, 31, 41].
Nonetheless, no significant variation in mortality be-
tween patients with preserved and reduced LVEF were
reported by other studies [19, 20, 26]. In the current
study, there was no substantial difference (Log rank test,
P = 0.807) in the survival status of patients with pre-
served and reduced ejection fraction. However, patients
with HFpEF had a relatively better survival status.
In the current study, multivariate cox regression ana-
lysis exhibited that the independent prognosticators of
all causes of death in patients with HF were advanced
age, low sodium level, high creatinine level, and absence
of medications like statins, ACEI, and Spironolactone.
Our findings were consistent with various studies; in a
prospective study conducted by Macín SM, et al. [19]
and Ojeda S, et al. [26] in Spain and a retrospective
study in USA by Owan TE et al. [13] reported that
advanced age, lower level of sodium, higher serum cre-
atinine level as a predictor of unfavorable outcome in
HF patients. In a retrospective study done by H. Kaneko
et al. [31] found that absence of statins in patients with
HFrEF medication prescription as a prognosticator of mor-
tality. In a randomized control trial conducted by Pitt B et
al. [42], it was reported that aldosterone blockers had a mo-
mentous importance in lowering morbidity and mortality
by decreasing atrial natriuretic peptide concentrations. The
study of left ventricular dysfunction (SOLVD) determined
that addition of ACEI in HF treatment had significantly de-
creased mortality and morbidity in patients with HFrEF
[43].
Study limitation
Our study had several limitations. First, this study was car-
ried out in a single center so the outcomes of the research
cannot be generalized to all medical centers. Second, the
sample size of the study population may not be sufficient
enough to detect statistically significant differences. Third,
the definition of HFrEF and HFpEF in the current study
was based on LVEF, and it therefore remains not certain
whether the study participants had objective documenta-
tion of diastolic dysfunction, as characterized by guiding
principle for the diagnosis of HFpEF.
Despite these limitations, we believe that our study
provides vital information on the clinical features and
prognosis of patients with HF. Moreover, it will give a
blue print for further clinical research in the area.
Conclusions
In the current study, majority of the patients presented
with HFpEF. As in other studies, women, hypertensive
and VHD etiologies were more predominant in patients
with HFpEF and takes CCB and anticoagulants. Patients
with HFrEF had IHD and DCMP etiologies. They usually
took Beta blockers and ACEI. There was no compelling
disparity in mortality between patients with HFrEF and
HFpEF. However, older age, lower sodium level, higher
creatinine level and absence of medications like ACEI,
spironolactone and statins independently predicted mor-
tality in all HF patients. These outcomes indicated that
further research should be conducted and several factors
should be considered for preserved or reduced LVEF
management.
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